Myocardial IschemiaKAPSSNCT07548879
Quantitative Analysis of Cardiac Muscle Perfusion
A study testing Magnetic Resonance Imaging with Contrast in people with Myocardial Ischemia, run by St. Anne's University Hospital Brno, Czech Republic at 1 site in Czechia.
Trial summary
Full quantitative perfusion of the myocardial wall using MRI is a difficult method for several reasons. First the perfusion algorithm is mostly only relatively available, usually available algorithms /e.g. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Myocardial Ischemia
- What is being tested?
- Magnetic Resonance Imaging with Contrast
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 35 participants
- Where
- 1 siteCzechia
- Study dates
- 1 Jun 2026to 30 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Signed informed consent
- Patients indicated for a non-invasive test for ischemic heart disease/chronic coronary syndrome
- Patients with intermittent chest pain and low to moderate probability of chronic coronary syndrome
Who cannot join
- Presence of relative or absolute contraindications to stress testing, including acute coronary syndrome, life-threatening arrhythmias, severe chronic obstructive pulmonary disease (COPD), or second- or third-degree atrioventricular (AV) block.
- Contraindications to MRI, such as severe claustrophobia, presence of ferromagnetic material or implants, or severe renal impairment.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Czechia1 site
St. Anne´s University Hospital Brno
Brno, 60200
Roman Panovský, MD, +420 543 18 2409, panovsky@fnusa.cz
Roman Panovský, MD
About this study
Full quantitative perfusion of the myocardial wall using MRI is a difficult method for several reasons. First the perfusion algorithm is mostly only relatively available, usually available algorithms /e.g. ISP/ shows not precise results according to our measurements, secondly based on signal physics and nature of MRI scans is not easy to get absolute numbers and specific new algorithms must be developed and tested. Such a tool is not only needed for some special cohort of patients, like 3-vessel disease, coronary artery disease or diffuse coronary artery involvement in coronary vasculopathy in patients after heart transplantation. Fully quantitative perfusion analysis is highly needed for nearly all cardiac patients to better characterise the health and status of the myocardium.
Read the detailed description
The aim of the study is to optimise the scanning and evaluation of stress perfusion with respect to the quantification of measurement results.
Cardiovascular diseases remain the leading cause of death among patients in developed countries. One of the most significant conditions within this group is ischemic heart disease (IHD), a state in which restricted blood flow through the coronary arteries results in myocardial ischemia.
At present, emphasis is placed on non-invasive diagnostic approaches to detect this condition. One such method is stress myocardial perfusion imaging.
Currently, this examination using magnetic resonance imaging (MRI) is mainly limited to qualitative assessment, in which the examiner evaluates perfusion defects based on a subjective visual assessment of myocardial blood flow, or semi-quantitative assessment, in which blood flow in individual myocardial segments is evaluated from the slope of signal-time curves. In this study, perfusion defects in individual segments will be assessed using quantitative analysis, i.e., direct calculation of blood flow in millilitres per gram of myocardial tissue, and the results will be compared with the aforementioned qualitative and semi-quantitative methods currently used in clinical practice.
In contrast, quantitative assessment of stress perfusion offers significant advantages, particularly the ability to provide an objective evaluation independent of the interpreting physician, improved diagnostic accuracy, and, importantly, the potential to diagnose patients with diffuse perfusion impairment across all vascular territories - for example, in those with three-vessel disease. However, fully quantified myocardial perfusion assessment is technically demanding and faces several limitations. The examination will be performed using a CE-marked Philips MRI system, with various frequencies and acquisition modules being evaluated.
The following quantitative CMR perfusion parameters will be analyzed:
Parameter Description Myocardial Blood Flow (MBF) Blood flow through the myocardium, expressed in ml/min/g of tissue. Measured for individual myocardial segments.
Myocardial Perfusion Reserve (MPR) Ratio of MBF during stress to MBF at rest: MPR = MBF_stress / MBF_rest, indicating the perfusion reserve.
Arterial Input Function (AIF) Contrast concentration in the left ventricle or aorta, serving as the reference input signal for MBF calculation.
Time to Peak (TTP) Time required for the myocardial signal to reach its maximum after bolus administration (indicator of delayed flow).
Upslope Slope of the rising phase of the perfusion curve - a relative measure of perfusion (often used in semi-quantitative analysis).
Peak Signal Intensity (PSI) Maximum signal value following contrast arrival (less commonly used as a standalone parameter).
Myocardial perfusion will be conducted according to the standard ESC perfusion protocol, using Gadolinium-based contrast agent (Gadovist) at a dose of 0.1 mmol/kg (0.1 ml/kg) administered at 3-5 ml/s, followed by 20 ml of saline flush. The contrast agent will be divided into two equal doses for stress and rest perfusion (0.05 ml/kg per perfusion). The stress agents used will be Adenosine (short-term infusion at 140 µg/kg/min using an infusion pump) or Regadenoson (400 µg intravenous bolus).
Patients with relative or absolute contraindications to stress testing will be excluded from the study, including those with acute coronary syndrome, life-threatening arrhythmias, severe COPD, second- or third-degree AV block, and patients with contraindications to MRI (ferromagnetic implants, severe renal failure, pregnancy).
The MRI protocol monitors contrast agent passage through the myocardium and subsequent washout for at least one minute in selected cardiac slices (typically three parallel short-axis slices from the apex to the base of the left ventricle). During the examination, basic physiological parameters are continuously monitored, including ECG, blood pressure, oxygen saturation (pO₂), and respiration. If necessary, the stress effect of the administered agent can be immediately reversed by administration of, for example, aminophylline. During scanning, changes in contrast concentration (signal intensity) are tracked over time. A targeted perfusion sequence (Philips DYNs_BTFE_3sl) will be used. For quantification purposes, this sequence will be complemented by a very short labeling sequence, which enables quantitative calculations while leaving the dynamic and pharmacological characteristics of the main perfusion sequence unaffected. After the examination, quantitative parameters from the perfusion sequence will be calculated to obtain the required perfusion metrics.
Analysis of the main perfusion parameters and other common cardiovascular metrics will be performed using Philips IntelliSpace Portal and CVI42 software.
The objective of the project is to optimize the scanning and evaluation process of stress perfusion MRI towards full quantification of measurement results, through collaboration between the clinical site and the MRI system manufacturer.
- Conditions
- Myocardial Ischemia
- Being tested
- Magnetic Resonance Imaging with Contrast
- Keywords
- Fully quantitative stress perfusion, CMR
- Medical subject headings
- Myocardial Ischemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magnetic Resonance Imaging with ContrastDiagnostic test
Myocardial perfusion will be conducted according to the standard ESC perfusion protocol, using Gadolinium-based contrast agent (Gadovist) at a dose of 0.1 mmol/kg (0.1 ml/kg) administered at 3-5 ml/s, followed by 20 ml of saline flush. The contrast agent will be divided into two equal doses for stress and rest perfusion (0.05 ml/kg per perfusion). The stress agents used will be Adenosine (short-term infusion at 140 µg/kg/min using an infusion pump) or Regadenoson (400 µg intravenous bolus).
Patients with relative or absolute contraindications to stress testing will be excluded from the study, including those with acute coronary syndrome, life-threatening arrhythmias, severe COPD, second- or third-degree AV block, and patients with contraindications to MRI (ferromagnetic implants, severe renal failure, pregnancy).
| Study group | Role | What they receive |
|---|---|---|
| Experimental Arm | Experimental | Patients clinically indicated for non-invasive exclusion of ischemic heart disease (IHD) will be enrolled in the study. All participants will undergo stress myocardial perfusion MRI in accordance with ESC (European Society of Cardiology) guidelines. The examination will form part of a standard cardiac MRI protocol. During the procedure, a vasoactive agent will be administered as part of routine clinical care, in accord current standards and recommendations. A quantitative and semi-quantitative analysis of myocardial blood flow will be performed from the acquired data, and the results of both analyses will be compared. In patients with documented perfusion abnormalities, selective coronary angiography will be performed in accordance with standard clinical practice. In cases of inconclusive test results, an additional stress test (e.g., myocardial scintigraphy) or CT coronary angiography will be performed. Receives: Diagnostic Test: Magnetic Resonance Imaging with Contrast |
What is being measured
The primary outcome is the main question the study is designed to answer.
The correlation between quantitative and semi-quantitative analyses
The primary outcome measure is the degree of correlation between quantitative and semi-quantitative analyses of rest and stress myocardial perfusion assessed by magnetic resonance imaging (MRI), evaluated both globally and in individual myocardial segments.
Measured: 1 day + up to 7 days after the examination
Secondary outcomes (2)
Ratio between MBF during stress and rest
Degree of correlation between quantitative analysis parameters: Myocardial Blood Flow (MBF) in ml/min/g for each myocardial segment and Myocardial Perfusion Reserve (MPR) as ratio between MBF during stress and rest - MPR = MBF_stress / MBF_rest with already established semiquantitive parameters: Time to Peak (TTP) as time for the myocardial signal to reach peak after contrast bolus (indicator of low blood flow), Upslope as the slope of signal intensity increase in signal intensity to time curve of the myocardium and Peak Signal Intensity (PSI) as the maximal signal intensity reached after contrast agent bolus
Measured: 1 day + up to 7 days after the indicated examination
The predictive value of quantitative and semi-quantitative MRI perfusion
The secondary outcome measure is the predictive value of quantitative and semi-quantitative MRI perfusion results relative to findings from invasive coronary angiography and other functional stress tests.
Measured: 1 day + up to 7 days after the indicated examination
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Apr 2026
- Study start1 Jun 2026 (estimated)
- Primary completion30 Dec 2029 (estimated)
- Study completion30 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial IschemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 35 participants (estimated)
Sponsor and investigators
- Lead sponsor
- St. Anne's University Hospital Brno, Czech Republic
- Sponsor type
- University, hospital or other
- Collaborators
- Philips Medical Systems
- Responsible party
- Sponsor
- Investigators
- Roman Panovský, MD, Principal investigator, St. Anne's University Hospital Brno, Czech Republic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07548879
- Sponsor's protocol ID
- 20V/2025
- Acronym
- KAPSS
- Status last verified
- Apr 2026
- First submitted
- 16 Apr 2026
- Last updated
- 23 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Quantitative Analysis of Cardiac Muscle Perfusion
- ClinicalTrials.gov ID
- NCT07548879
- Acronym / sponsor ID
- KAPSS / 20V/2025
- Conditions
- Myocardial Ischemia
- Keywords
- Fully quantitative stress perfusion, CMR
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 35 participants (estimated)
- Lead sponsor
- St. Anne's University Hospital Brno, Czech RepublicUniversity, hospital or other
- Collaborators
- Philips Medical Systems
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- 30 Dec 2029 (estimated)
- Study completion
- 30 Dec 2029 (estimated)
- First posted
- 23 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Full quantitative perfusion of the myocardial wall using MRI is a difficult method for several reasons. First the perfusion algorithm is mostly only relatively available, usually available algorithms /e.g. ISP/ shows not precise results according to our measurements, secondly based on signal physics and nature of MRI scans is not easy to get absolute numbers and specific new algorithms must be developed and tested. Such a tool is not only needed for some special cohort of patients, like 3-vessel disease, coronary artery disease or diffuse coronary artery involvement in coronary vasculopathy in patients after heart transplantation. Fully quantitative perfusion analysis is highly needed for nearly all cardiac patients to better characterise the health and status of the myocardium.
Detailed description
The aim of the study is to optimise the scanning and evaluation of stress perfusion with respect to the quantification of measurement results.
Cardiovascular diseases remain the leading cause of death among patients in developed countries. One of the most significant conditions within this group is ischemic heart disease (IHD), a state in which restricted blood flow through the coronary arteries results in myocardial ischemia.
At present, emphasis is placed on non-invasive diagnostic approaches to detect this condition. One such method is stress myocardial perfusion imaging.
Currently, this examination using magnetic resonance imaging (MRI) is mainly limited to qualitative assessment, in which the examiner evaluates perfusion defects based on a subjective visual assessment of myocardial blood flow, or semi-quantitative assessment, in which blood flow in individual myocardial segments is evaluated from the slope of signal-time curves. In this study, perfusion defects in individual segments will be assessed using quantitative analysis, i.e., direct calculation of blood flow in millilitres per gram of myocardial tissue, and the results will be compared with the aforementioned qualitative and semi-quantitative methods currently used in clinical practice.
In contrast, quantitative assessment of stress perfusion offers significant advantages, particularly the ability to provide an objective evaluation independent of the interpreting physician, improved diagnostic accuracy, and, importantly, the potential to diagnose patients with diffuse perfusion impairment across all vascular territories - for example, in those with three-vessel disease. However, fully quantified myocardial perfusion assessment is technically demanding and faces several limitations. The examination will be performed using a CE-marked Philips MRI system, with various frequencies and acquisition modules being evaluated.
The following quantitative CMR perfusion parameters will be analyzed:
Parameter Description Myocardial Blood Flow (MBF) Blood flow through the myocardium, expressed in ml/min/g of tissue. Measured for individual myocardial segments.
Myocardial Perfusion Reserve (MPR) Ratio of MBF during stress to MBF at rest: MPR = MBF_stress / MBF_rest, indicating the perfusion reserve.
Arterial Input Function (AIF) Contrast concentration in the left ventricle or aorta, serving as the reference input signal for MBF calculation.
Time to Peak (TTP) Time required for the myocardial signal to reach its maximum after bolus administration (indicator of delayed flow).
Upslope Slope of the rising phase of the perfusion curve - a relative measure of perfusion (often used in semi-quantitative analysis).
Peak Signal Intensity (PSI) Maximum signal value following contrast arrival (less commonly used as a standalone parameter).
Myocardial perfusion will be conducted according to the standard ESC perfusion protocol, using Gadolinium-based contrast agent (Gadovist) at a dose of 0.1 mmol/kg (0.1 ml/kg) administered at 3-5 ml/s, followed by 20 ml of saline flush. The contrast agent will be divided into two equal doses for stress and rest perfusion (0.05 ml/kg per perfusion). The stress agents used will be Adenosine (short-term infusion at 140 µg/kg/min using an infusion pump) or Regadenoson (400 µg intravenous bolus).
Patients with relative or absolute contraindications to stress testing will be excluded from the study, including those with acute coronary syndrome, life-threatening arrhythmias, severe COPD, second- or third-degree AV block, and patients with contraindications to MRI (ferromagnetic implants, severe renal failure, pregnancy).
The MRI protocol monitors contrast agent passage through the myocardium and subsequent washout for at least one minute in selected cardiac slices (typically three parallel short-axis slices from the apex to the base of the left ventricle). During the examination, basic physiological parameters are continuously monitored, including ECG, blood pressure, oxygen saturation (pO₂), and respiration. If necessary, the stress effect of the administered agent can be immediately reversed by administration of, for example, aminophylline. During scanning, changes in contrast concentration (signal intensity) are tracked over time. A targeted perfusion sequence (Philips DYNs_BTFE_3sl) will be used. For quantification purposes, this sequence will be complemented by a very short labeling sequence, which enables quantitative calculations while leaving the dynamic and pharmacological characteristics of the main perfusion sequence unaffected. After the examination, quantitative parameters from the perfusion sequence will be calculated to obtain the required perfusion metrics.
Analysis of the main perfusion parameters and other common cardiovascular metrics will be performed using Philips IntelliSpace Portal and CVI42 software.
The objective of the project is to optimize the scanning and evaluation process of stress perfusion MRI towards full quantification of measurement results, through collaboration between the clinical site and the MRI system manufacturer.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Experimental Arm | Experimental | Diagnostic Test: Magnetic Resonance Imaging with ContrastPatients clinically indicated for non-invasive exclusion of ischemic heart disease (IHD) will be enrolled in the study. All participants will undergo stress myocardial perfusion MRI in accordance with ESC (European Society of Cardiology) guidelines. The examination will form part of a standard cardiac MRI protocol. During the procedure, a vasoactive agent will be administered as part of routine clinical care, in accord current standards and recommendations. A quantitative and semi-quantitative analysis of myocardial blood flow will be performed from the acquired data, and the results of both analyses will be compared. In patients with documented perfusion abnormalities, selective coronary angiography will be performed in accordance with standard clinical practice. In cases of inconclusive test results, an additional stress test (e.g., myocardial scintigraphy) or CT coronary angiography will be performed. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Signed informed consent
- Patients indicated for a non-invasive test for ischemic heart disease/chronic coronary syndrome
- Patients with intermittent chest pain and low to moderate probability of chronic coronary syndrome
Key exclusion criteria (2 listed)
- Presence of relative or absolute contraindications to stress testing, including acute coronary syndrome, life-threatening arrhythmias, severe chronic obstructive pulmonary disease (COPD), or second- or third-degree atrioventricular (AV) block.
- Contraindications to MRI, such as severe claustrophobia, presence of ferromagnetic material or implants, or severe renal impairment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magnetic Resonance Imaging with ContrastMyocardial perfusion will be conducted according to the standard ESC perfusion protocol, using Gadolinium-based contrast agent (Gadovist) at a dose of 0.1 mmol/kg (0.1 ml/kg) administered at 3-5 ml/s, followed by 20 ml of saline flush. The contrast agent will be divided into two equal doses for stress and rest perfusion (0.05 ml/kg per perfusion). The stress agents used will be Adenosine (short-term infusion at 140 µg/kg/min using an infusion pump) or Regadenoson (400 µg intravenous bolus). Patients with relative or absolute contraindications to stress testing will be excluded from the study, including those with acute coronary syndrome, life-threatening arrhythmias, severe COPD, second- or third-degree AV block, and patients with contraindications to MRI (ferromagnetic implants, severe renal failure, pregnancy). | Diagnostic test | Experimental Arm |
Primary outcome
The correlation between quantitative and semi-quantitative analyses
Time frame: 1 day + up to 7 days after the examination
The primary outcome measure is the degree of correlation between quantitative and semi-quantitative analyses of rest and stress myocardial perfusion assessed by magnetic resonance imaging (MRI), evaluated both globally and in individual myocardial segments.
2 secondary outcomes
Ratio between MBF during stress and rest
Time frame: 1 day + up to 7 days after the indicated examination
The predictive value of quantitative and semi-quantitative MRI perfusion
Time frame: 1 day + up to 7 days after the indicated examination
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Myocardial Ischemia
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
RecruitingEarly Phase 1
Thiamine Intervention and Coronary Artery Bypass Grafting
Coronary Heart Disease, Coronary Artery Bypass Grafting
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Roman Panovský, MD principal investigator
St. Anne's University Hospital Brno, Czech Republic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Magnetic Resonance Imaging with Contrast in people with Myocardial Ischemia, run by St. Anne's University Hospital Brno, Czech Republic at 1 site in Czechia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Roman Panovský, MD (+420 543 18 2409, panovsky@fnusa.cz), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The correlation between quantitative and semi-quantitative analyses (time frame: 1 day + up to 7 days after the examination). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2026.